downloadCannabics Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and production of proprietary technologies for treating a wide range of indications through medical cannabis.

The flagship product of Cannabics is the Cannabics SR capsule, a sustained release capsule that provides palliative care to patients suffering from certain types of cancer. The Cannabics SR capsule uses a patented formulation and contains cannabinoids pure concentrate. Cannabinoids are extracted from various strains of the cannabis plant selected and bred by the company. Each capsule provides 10 to 12 hours of therapeutic effects, which allows for once-per-day dosage.

Cannabics Pharmaceuticals, Inc. also supplies other products in the company line, including the condensed Cannabis VP pill for standard vaporizers, and the capsule Cannabics IN for dry powder inhalers. As of 2013, the products of the company have circulated through five hospitals in Israel, where medical marijuana use is permitted for cancer patients and for treatment for pain-related illnesses.

Cannabics Pharmaceuticals, Inc., through its research and development extension in Israel, is developing a pipeline of advanced cannabinoid-based therapies. With the company’s collaboration with major medical centers in the U.S., Israel, and Europe, Cannabics is now launching clinical studies investigating the beneficial effects of their products in a wide range of medical indications.

Cannabics Pharmaceuticals, Inc. is a subsidiary of Cannabics, Inc., and was founded in 2012 by research experts in the fields of molecular biology, cancer research, and pharmacology.  The company, which is based in Bethseda, Maryland, was known as Thrust Energy Corp until 2011, and as American Mining Corporation until June in 2014.

Cannabics Pharmaceuticals, Inc. is traded in the OTC Markets under the stock symbol CNBX. The company’s key executives are Dr. Zohar Koren, CEO and Co-founder; Dr. Eyal Ballan, CTO and Co-founder; and Itamar Borochov, Marketing VP.


Yahoo! Finance: CNBX News

Latest Financial News for CNBX

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration along with a Pre-IND meeting request.

Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells. Study results indicate a 35% prolonged survival rate in mice exposed to RCC-33 in comparison with sham control mice, as shown by Kaplan-Meier survival curve analysis, P-value = 0.08 (Figure 1).

Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021, that said study results showing "a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice," are said to have statistical significance with p ≤ 0.016.

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice. The final study results demonstrate a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice (p £ 0.016).

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cancer in nude-mice. The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice. Both groups were inoculated with colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Interim results of a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p-value=0.022. Study is ongoing.